...lside Hospital campus of The Feinstein Institute f...ene that appears to influence intelligence. Workin...ers Center for Genetics and Genomics in Boston, th...ints of individuals with schizophrenia, a neuropsy...rment, and compared them with healthy volunteers. ...
...t to mention the cleaning product industry, repeat...ity School of Medicine microbiologist is raising t...iral infections have benefits. , Stanley Falkow, P...n Cancer Research, is publishing his thoughts on t...journal Cell, in which he asks, "Is persistent bac...
...the world has revealed that nature encourages biod...es. The landmark study, conducted by 33 ecologists...sue of the journal Science, conclusively demonstra...rtance to tropical forests. , Helene Muller-Landau...ity of Minnesota,s College of Biological Sciences,...
Other Biology News:Feinstein researchers identify intelligence gene 2Learning to love bacteria: Stanford scientist highlights bugs' benefits 2Learning to love bacteria: Stanford scientist highlights bugs' benefits 3Underdogs in the understory: Study suggests nature favors rarer trees 2(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
(Date:12/1/2009)NEW YORK, Dec. 1 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Chromium - Global Market Trends ,, http://www.reportlinker.com/p0164494/Chromium--
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9... Pa., Feb. 18 Jennifer Brownstein, Art Director a...09 Rising Star by the Healthcare Businesswomen,s A...ng professionals in various sectors of the healthc...ogy, advertising, public relations, medical educat...rate members, Rising Stars represent various caree...
...HOUSAND OAKS, Calif., Feb. 18 Amgen Inc. (Nasdaq:...rug Administration (FDA) has accepted Amgen,s subm...BLA) for denosumab, an investigational RANK Ligand...eking FDA approval are treatment and prevention of...eatment and prevention of bone loss in patients un...
... Finder to Speed up the Peer Review Process! , , ...TC Bulletin Board: CLXS), a leading developer of s...nnounced today that the American Association for C...eviewer Finder and Journal Dashboard applications ...o: http://www.newscom.com/cgi-bin/prnh/20090107/...
Other Biology Technology:Jennifer Brownstein, of CONNEXION Healthcare, Honored as 'Rising Star' by Healthcare Businesswomen's Association 2FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab 2FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab 3FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab 4FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab 5FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab 6American Association for Cancer Research (AACR) Deploys Collexis' Reviewer Finder and Journal Dashboard Applications 2American Association for Cancer Research (AACR) Deploys Collexis' Reviewer Finder and Journal Dashboard Applications 3Mouse Anti-Human CDC2L5 Monoclonal Antibody, Unconjugated, Clone 1B3-1B11 from Novus Biologicals
GenomePlex Whole Genome Amplification (WGA) kit from Sigma-Aldrich
...r Vector is a derivative of the pAcHLT-A Vector (C...orescent protein (BFP), followed by a 6xHis tag an... expressed as BFP-6xHis fusion proteins when clone...es (EcoR I, Stu I, Sac I, Not I, Pst I, Kpn I, Sma...
Histology, Immunohistochemistry & Tissue Array Services from Dominion Pharmakine S.L.
Biology Products: